The US Preventive Services Task Force (USPSTF) has updated its recommendation on cervical cancer screening. The new recommendation emphasizes the importance of widespread cervical cancer screening, which has significantly reduced cervical cancer deaths from 2.8 to 2.3 per 100,000 women from 2000 to 2015. The USPSTF recommends: - **For women aged 21 to 29 years:** Screening every 3 years with cervical cytology alone. - **For women aged 30 to 65 years:** Screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with both tests (cotesting). - **Against screening:** Women younger than 21 years, women older than 65 years who have had adequate prior screening and are not otherwise at high risk, and women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer. The USPSTF concludes with high certainty that the benefits of these screening strategies outweigh the harms. The decision to stop screening at age 65 years is supported by evidence showing that cervical cancer incidence and mortality decline after this age. The USPSTF also highlights the importance of ensuring adequate follow-up and appropriate treatment to maximize the benefits of screening.The US Preventive Services Task Force (USPSTF) has updated its recommendation on cervical cancer screening. The new recommendation emphasizes the importance of widespread cervical cancer screening, which has significantly reduced cervical cancer deaths from 2.8 to 2.3 per 100,000 women from 2000 to 2015. The USPSTF recommends: - **For women aged 21 to 29 years:** Screening every 3 years with cervical cytology alone. - **For women aged 30 to 65 years:** Screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with both tests (cotesting). - **Against screening:** Women younger than 21 years, women older than 65 years who have had adequate prior screening and are not otherwise at high risk, and women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer. The USPSTF concludes with high certainty that the benefits of these screening strategies outweigh the harms. The decision to stop screening at age 65 years is supported by evidence showing that cervical cancer incidence and mortality decline after this age. The USPSTF also highlights the importance of ensuring adequate follow-up and appropriate treatment to maximize the benefits of screening.